Back to top
more

Grifols (GRFS)

(Delayed Data from NSDQ)

$6.48 USD

6.48
1,106,086

+0.10 (1.57%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $6.49 +0.01 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Is Grifols (GRFS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Grifols (GRFS) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

New Strong Sell Stocks for January 13th (Revised)

GEVO, GRFS and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2023.

New Strong Sell Stocks for January 13th

GEVO, GRFS and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2023.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

New Strong Sell Stocks for January 6th

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

New Strong Sell Stocks for September 22nd

MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021

Moving Average Crossover Alert: Grifols (GRFS)

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

New Strong Sell Stocks for March 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Moving Average Crossover Alert: Grifols

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Is Grifols (GRFS) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Should Value Investors Consider Grifols (GRFS) Stock Now?

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

Sanghamitra Saha headshot

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

How Grifols (GRFS) Stock Stands Out in a Strong Industry

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Actinium Treats First Patient in AML Study on Actimab-A Combo

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should Know

Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 5th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today: